We will take a simple, efficient approach to preparing product launches, utilizing shared,
best in class platforms and ways of working that enable fast decision-making and cost-effective
growth. We will focus on transforming treatment in underserved markets, such as insomnia, and
building new markets, such as cerebral vasospasm, using scientific and medical evidence to engage
effectively with experts in the field and with payors. We plan to remain flexible and nimble
in the way we commercialize our portfolio, building the core capabilities required to successfully
launch our products, while also being prepared to enter into partnerships where we need support to
reach a primary care market.
We have established commercial operations in the US and Japan, with experienced leadership
teams and strategic locations. We have also established a robust and lean global supply chain function to
ensure consistent supplies of our innovative medicines to patients.